This study is the first study in the literature that highlights the impact of an SGLT2 inhibitor on CABG patients with/without T2DM and with/without CKD undergoing a rehabilitation program and compares the influence of an SGLT2 inhibitor on H-FABP levels. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.